Axsome Therapeutics, Inc. (AXSM) stock
AXSMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 8/30
$134.00−1.95 (-1.43%)
Close on Nov 18, 2026Market cap $7.02BP/E –Yield –
Axsome Therapeutics total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Axsome Therapeutics's total debt was $187.96M at Jun 30, 2026. For fiscal 2025 it was $187.75M, up 3.9% from the year before. The highest annual figure on record is $187.75M in fiscal 2025.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $187.75M | +3.9% |
| FY2024 | Dec 31, 2024 | $180.71M | +1.5% |
| FY2023 | Dec 31, 2023 | $178.07M | +88.9% |
| FY2022 | Dec 31, 2022 | $94.26M | +92.0% |
| FY2021 | Dec 31, 2021 | $49.09M | +1.6% |
| FY2020 | Dec 31, 2020 | $48.32M | +142.4% |
| FY2019 | Dec 31, 2019 | $19.93M | +188.5% |
| FY2018 | Dec 31, 2018 | $6.91M | -30.4% |
| FY2017 | Dec 31, 2017 | $9.93M | +2.0% |
| FY2016 | Dec 31, 2016 | $9.74M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $187.96M | +0.2% |
| Q1 FY2026 | Mar 31, 2026 | $187.85M | +3.6% |
| Q4 FY2025 | Dec 31, 2025 | $187.75M | +3.9% |
| Q3 FY2025 | Sep 30, 2025 | $187.64M | +4.2% |
| Q2 FY2025 | Jun 30, 2025 | $187.54M | +4.6% |
| Q1 FY2025 | Mar 31, 2025 | $181.38M | +1.5% |
| Q4 FY2024 | Dec 31, 2024 | $180.71M | +1.5% |
| Q3 FY2024 | Sep 30, 2024 | $180.00M | +1.4% |
| Q2 FY2024 | Jun 30, 2024 | $179.33M | +1.4% |
| Q1 FY2024 | Mar 31, 2024 | $178.69M | +21.1% |
| Q4 FY2023 | Dec 31, 2023 | $178.07M | +88.9% |
| Q3 FY2023 | Sep 30, 2023 | $177.45M | +88.9% |
| Q2 FY2023 | Jun 30, 2023 | $176.82M | +89.2% |
| Q1 FY2023 | Mar 31, 2023 | $147.62M | +199.3% |
| Q4 FY2022 | Dec 31, 2022 | $94.26M | +92.0% |
| Q3 FY2022 | Sep 30, 2022 | $93.91M | +91.0% |
| Q2 FY2022 | Jun 30, 2022 | $93.46M | +91.2% |
| Q1 FY2022 | Mar 31, 2022 | $49.31M | +1.5% |
| Q4 FY2021 | Dec 31, 2021 | $49.09M | +1.6% |
| Q3 FY2021 | Sep 30, 2021 | $49.17M | +2.4% |
| Q2 FY2021 | Jun 30, 2021 | $48.88M | +140.9% |
| Q1 FY2021 | Mar 31, 2021 | $48.60M | +141.6% |
| Q4 FY2020 | Dec 31, 2020 | $48.32M | +142.4% |
| Q3 FY2020 | Sep 30, 2020 | $48.03M | +143.1% |
| Q2 FY2020 | Jun 30, 2020 | $20.29M | +3.6% |
| Q1 FY2020 | Mar 31, 2020 | $20.11M | +3.9% |
| Q4 FY2019 | Dec 31, 2019 | $19.93M | +188.5% |
| Q3 FY2019 | Sep 30, 2019 | $19.76M | +155.7% |
| Q2 FY2019 | Jun 30, 2019 | $19.58M | +131.1% |
| Q1 FY2019 | Mar 31, 2019 | $19.35M | +110.2% |
| Q4 FY2018 | Dec 31, 2018 | $6.91M | -30.4% |
| Q3 FY2018 | Sep 30, 2018 | $7.73M | -23.4% |
| Q2 FY2018 | Jun 30, 2018 | $8.47M | -15.1% |
| Q1 FY2018 | Mar 31, 2018 | $9.21M | -6.6% |
| Q4 FY2017 | Dec 31, 2017 | $9.93M | +2.0% |
| Q3 FY2017 | Sep 30, 2017 | $10.09M | – |
| Q2 FY2017 | Jun 30, 2017 | $9.97M | – |
| Q1 FY2017 | Mar 31, 2017 | $9.86M | – |
| Q4 FY2016 | Dec 31, 2016 | $9.74M | – |
See a number that looks wrong?